

2000

가 2 2000

2000 1 12 32,088 10 가

1960 , 1970 71.9 , 가 25,060(78.1%) 2).

가 )

1989 90 1993 94 1.

(Fig. 1)<sup>1)</sup>. 2000

1994 6 4 가 6

3 1 10 12 가 가

9 3,470 8 가

가 가 2000 89.2%(28,618 ) (Fig. 2).

가 2000




Fig. 1. (1963 2000 ; 2

2. 12 422.4 (Fig. 4).

가 292.2 가 4. MMR  
 258.2 , MMR  
 136.5 (Fig. 3). 21,188  
 3. 74.8% 15,852  
 24 MMR 1 , 1997  
 4 5 가 4 6 MMR 2  
 6 가 10 7 9 4,555 885  
 19.4% 2 MMR  
 10 가 1  
 473.3 가 12 15




Fig. 2. (2000 2 , )




Fig. 3. (2000 2 , )




Fig. 4. (2000 ).




Fig. 5. 1 MMR (2000. 1 2000. 12).




Fig. 6. MMR (2000 ).

14 : 8 1 2001

30% (Fig. 5).  
1 (24 )  
1 , 7  
1  
2  
(Fig. 6).

5. 2000

2000 24  
13.5%  
, 7 15  
67.6%

81.1%  
24  
1  
, 7  
1  
가  
가가  
1 , 2  
<sup>3)</sup>. 1997 4 6 2  
가 2

1.

3 5  
, 1997 2  
2001  
가 <sup>4)</sup>.  
6  
2 95%  
, 7  
(Catch-Up Programme)

,  
2.  
, , (7 18 )  
94 , , 282  
, , 23,000  
<sup>5)</sup>.

가  
( , MMR )

가 (Behring) 가(IgG)  
(Enzygnost Anti-Mea-  
sles Virus IgG) (Enzyme  
linked immunosorbent assay, ELISA)

16

3.  
1)  
94 282 가  
, 22,584  
20,715 (91.7%),  
18,407 (81.5%)

18,139 (80.3%)  
18,139  
( ‘ ’)

2)  
8,912 49.1%  
, 9,227 50.9%  
가 52.8%, 41.4%, 49.1%

3)  
MMR  
가 1985  
3 14,032

3,781 (26.9%)  
 ( ' '), 가 , 2  
 ( ' ') , 89.9%,  
 1,455 (10.4%) . 86.2%  
 4) (2)  
 12 15 3  
 1 4 6 2 0 , 1 , 2 가 81.9%, 84.5%,  
 . 1 MMR 88.5% 가 .  
 가 1985 (3)  
 3 14,032 , 2  
 1997 85.0% 92.4%, 92.4% 95.2  
 3 4,801 %, 94.0% 97.8%  
 . 1 84.2  
 %, 2 37.7% . 1  
 86.2%, 2 37.7% , (4)  
 1 80.2% . 가 가  
 . 2  
 90.1%, 92.9%, 2 38.7%, 39.1 4.4% .  
 % . 6) 2000  
 5) (1)  
 89.4% ' , 1  
 85.5%, ( )가  
 92.8%, 94.5% 가  
 가 . 2 188 54 1  
 94% (84.7 93.3) , 가 , 14,032  
 3 94% (94.3 94.7%) (Fig. 7). 4,414 31.5% . 94  
 (1) 34 (36.2%)  
 1 20 (21.3%) .




Fig. 7. (2000. 12).

(2) 가 가 , , 가 1  
가 가 1 ,

(3) 가 가  
가 가 2

92.8% 81.4% 98.0% 가 가 2  
91.4% 98.0% 가 가 2  
% 3 .

(Catch-up Campaign)

1. , 84.2%  
2000 12 , 95%<sup>6)</sup>  
, , 89.4%, 1 3 (2001 2  
6% 1 ) .

<sup>6)</sup>. 2000

(7 15 ) 가 1)  
32,088 67.6% 7),  
(7 11 ) 14.  
5%, (12 15 ) 7.2% ,  
12.0% 84.2  
% .  
가 2000

, 2000 12  
, , 1/3  
2001

2. 2  
가 1  
93%  
, '97 2  
40%

- 1) . 2000 , 00-
- 6. , 2000:79
- 2) . 2000  
( ) .
- 3) CDC. Epidemiology and prevention of vaccine-preventable diseases, 6th ed, 2000:127-9.
- 4) . 가 5  
. 2001:1-16.
- 5) .  
2000.
- 6) WHO. Guidelines for epidemic preparedness and response to measles outbreaks, 19, Geneva, Switzerland, 1999:3-4.
- 7) . ( ) .
- 8) CDC. Measles, mumps and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. MMWR 1998;47(RR-8):15-6.